{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:40:20Z","timestamp":1777934420663,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Febrile neutropenia (FN) is one of the dose-limiting adverse effects of chemotherapy. Granulocyte-Colony Stimulating Factors (G-CSFs) minimize the incidence of FN and reduce the risk of neutropenia complications. This study was conducted to address the prescription pattern of G-CSF for primary prophylaxis of FN during the first cycle of chemotherapy in solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This prospective observational study was done to investigate the G-CSF prescription pattern in patients receiving the first cycle of chemotherapy for solid tumors and compare it with the NCCN guideline recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Based on the guideline, prophylactic G-CSF administration was indicated in 26 of the 96 patients (27.1%) and all of them received G-CSF. On the other hand, 70 patients (72.9%) did not meet the guideline criteria for prophylaxis, but 60 (62.5%) of them received G-CSF. Seven doses of pegfilgrastim and 165 doses of filgrastim were used inappropriately in the study population, which was associated with an economic burden of about 224.7 million IRR (5350 USD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taken together, inconsistencies with the guideline were observed in this prospective evaluation, suggesting that submitting rationalized policies to decrease G-CSF prescription, especially in patients with a lower or intermediate FN risk, yields substantial cost savings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155219875507","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T01:52:07Z","timestamp":1571190727000},"page":"428-433","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Appropriateness of using granulocyte colony-stimulating factor (G-CSF) for primary prophylaxis of febrile neutropenia in solid tumors"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-9546","authenticated-orcid":false,"given":"Elahe","family":"Laali","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinous","family":"Fazli","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanambar","family":"Sadighi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine,Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Mohammadi","sequence":"additional","affiliation":[{"name":"Department of Clinical pharmacy, School of Pharmacy, Alborz University of Medical Sciences, Alborz Province, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kheirollah","family":"Gholami","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Jahangard-Rafsanjani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Breast Disease Research Center, Tehran university of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"bibr1-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25332"},{"key":"bibr2-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1165-6"},{"key":"bibr3-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20983"},{"key":"bibr4-1078155219875507","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725040-00006"},{"key":"bibr5-1078155219875507","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2005.0031"},{"key":"bibr6-1078155219875507","unstructured":"network ncc. version 2.2018 myeloid growth factor. 2018."},{"key":"bibr7-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8823"},{"key":"bibr8-1078155219875507","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2003.0038"},{"key":"bibr9-1078155219875507","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262001-00005"},{"key":"bibr10-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0797-z"},{"key":"bibr11-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2012.000662"},{"key":"bibr12-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1700\/1660.18158"},{"key":"bibr13-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1177\/1078155208091249"},{"key":"bibr14-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct1210890"},{"key":"bibr15-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-2067-1"},{"key":"bibr16-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31820dc075"},{"key":"bibr17-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-3036-7"},{"key":"bibr18-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr152"},{"key":"bibr19-1078155219875507","first-page":"248","volume":"5","author":"Alshehri A","year":"2017","journal-title":"J Pharmacovigilance"},{"key":"bibr20-1078155219875507","first-page":"85","volume":"10","author":"Mousavi S","year":"2016","journal-title":"Int J Hematology-Oncology Stem Cell Res"},{"key":"bibr21-1078155219875507","doi-asserted-by":"crossref","unstructured":"Zullo AR, Lou U, Cabral SE, et\u00a0al. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia.\n                      J Oncol Pharm Practice\n                      2019; 25: 1357\u20131365.","DOI":"10.1177\/1078155218792698"},{"key":"bibr22-1078155219875507","first-page":"9","volume":"4","author":"Butler TW","year":"2014","journal-title":"J Hematol Oncol Pharm"},{"key":"bibr23-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2686-9"},{"key":"bibr24-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3421-x"},{"key":"bibr25-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G516"},{"key":"bibr26-1078155219875507","doi-asserted-by":"publisher","DOI":"10.1177\/030089160909500214"},{"key":"bibr27-1078155219875507","first-page":"5","volume":"4","author":"Butler TW","year":"2014","journal-title":"J Hematol Oncol Pharm"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219875507","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219875507","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219875507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:21:54Z","timestamp":1777688514000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219875507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1177\/1078155219875507"],"URL":"https:\/\/doi.org\/10.1177\/1078155219875507","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]}}}